Partnerships with Industry

Industry Collaboration

Genentech - [Press Release]
ABC2 is entering its fifth year of collaboration with Genentech to push new drug therapies into the clinic for the benefit of brain cancer patients. Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Under the collaboration, ABC2 shares development expenses with Genentech and provides access to its resources, including relationships with leading researchers and clinicians.

Genentech, in turn, offers its world-renowned experience in designing and developing pioneering drug therapies. If Genentech markets any resulting products, ABC2 will receive royalties on product sales to invest back into its work. This revolutionary partnership aims to significantly improve the prospects for the treatment of brain cancer and advance the search for a cure.

CombinatoRx - [Press Release]
In 2005, ABC2 formed a collaborative with the biotechnology company CombinatoRx to screen thousands of combinations of drugs previously untried as potential therapeutic agents against the most complex and life-threatening forms of brain cancer. This relationship is particularly advantageous as the CombinatoRx library contains a great number of individual drugs that, though already approved for use, might never have been tested in combination as treatments for brain cancer. Any positive results from these screenings will move directly into testing on partner Duke University’s animal models of brain cancer.

Additionally, because the drug compounds are approved by global regulatory agencies, this process could lead to advanced clinical trials in patients with complex brain cancers. Positive in vitro results have been detected in several such new combinations. Study data was presented at the April 2006 annual meeting of the American Association for Cancer Research.

Ingenuity - [Press Release]
ABC2 partnered with Ingenuity in 2003 to test existing chemotherapeutic agents against recently discovered gene defects associated with brain cancer pathways. Leading researchers from Cedars-Sinai Medical Center, University of Michigan, University of California, San Francisco, and University of California, Los Angeles participate in the program.